On September 8, 2023 Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, reported that they have signed a LOI for long-term strategic collaboration on Mabwell’s multiple ADC projects (Press release, Mabwell Biotech, SEP 8, 2023, View Source [SID1234635034]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mabwell has had multiple innovative products in clinical studies or preclinical research by their world-leading ADC technology platforms and CMC development capabilities. WuXi XDC will make further efforts to accelerate global layout of Mabwell’s R&D and commercialization, cost reduction and R&D efficiency improvement by their leading antibody-drug conjugate production technology platform and integration capabilities.